These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10185985)

  • 1. Anticonvulsants: choices and costs. Based on a presentation by Nina Graves, PharmD, FCCP.
    Am J Manag Care; 1998 Sep; 4(9 Suppl):S463-7; discussion S468-74. PubMed ID: 10185985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011.
    Italiano D; Capuano A; Alibrandi A; Ferrara R; Cannata A; Trifirò G; Sultana J; Ferrajolo C; Tari M; Tari DU; Perrotta M; Pagliaro C; Rafaniello C; Spina E; Arcoraci V
    Br J Clin Pharmacol; 2015 Jun; 79(6):1010-9. PubMed ID: 25556909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing antiepileptic drugs: should patients be switched on the basis of cost?
    Jobst BC; Holmes GL
    CNS Drugs; 2004; 18(10):617-28. PubMed ID: 15270592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of newer antiepileptic drugs.
    Beghi E; Atzeni L; Garattini L
    CNS Drugs; 2008; 22(10):861-75. PubMed ID: 18788837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some common issues in the use of antiepileptic drugs.
    Asconapé JJ
    Semin Neurol; 2002 Mar; 22(1):27-39. PubMed ID: 12170391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
    Fishman J; Kalilani L; Song Y; Swallow E; Wild I
    J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Markowitz MA; Mauskopf JA; Halpern MT
    Neurology; 1998 Oct; 51(4):1026-33. PubMed ID: 9781524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios.
    Lathers CM; Schraeder PL; Claycamp HG
    J Clin Pharmacol; 2003 May; 43(5):491-503. PubMed ID: 12751270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-interventional surveillance study of adverse events in patients with epilepsy.
    Cramer JA; Steinborn B; Striano P; Hlinkova L; Bergmann A; Bacos I; Baukens C; Buyle S
    Acta Neurol Scand; 2011 Jul; 124(1):13-21. PubMed ID: 21039365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
    Chisholm D;
    Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing?
    Palmieri C; Canger R
    CNS Drugs; 2002; 16(11):755-64. PubMed ID: 12383031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries.
    Heaney DC; Shorvon SD; Sander JW; Boon P; Komarek V; Marusic P; Dravet C; Perucca E; Majkowski J; Lima JL; Arroyo S; Tomson T; Ried S; van Donselaar C; Eskazan E; Peeters P; Carita P; Tjong-a-Hung I; Myon E; Taieb C
    Epilepsia; 2000; 41 Suppl 5():S37-44. PubMed ID: 11045437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection criteria for the clinical use of the newer antiepileptic drugs.
    Deckers CL; Knoester PD; de Haan GJ; Keyser A; Renier WO; Hekster YA
    CNS Drugs; 2003; 17(6):405-21. PubMed ID: 12697000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET).
    Boon P; Dejonghe P; Legros B; Sadzot B; van Rijckevorsel K; Schmedding E
    Seizure; 2008 Jun; 17(4):350-7. PubMed ID: 18203628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?
    Adab N
    CNS Drugs; 2006; 20(10):791-800. PubMed ID: 16999450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of old versus new antiepileptic drugs on costs and patient reported outcomes among older adults.
    Almalag HM; Alzahrani H; Al-Hussain F; Alsemari A; De Vol EB; Almarzouqi MR; AlRuthia YS
    Geriatr Nurs; 2018 Nov; 39(6):669-675. PubMed ID: 29859697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics Aspects of Antiepileptic Drugs in Pediatric Patients with Epilepsy.
    Kopciuch D; Fliciński J; Steinborn B; Winczewska-Wiktor A; Paczkowska A; Zaprutko T; Ratajczak P; Nowakowska E; Kus K
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.